- Home
- NAMS vs GOF Comparison
NAMS vs GOF Comparison
Compare NAMS & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- GOF
- Stock Information
- Founded
- NAMS 2019
- GOF 2006
- Country
- NAMS Netherlands
- GOF United States
- Employees
- NAMS N/A
- GOF N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- GOF Finance/Investors Services
- Sector
- NAMS Health Care
- GOF Finance
- Exchange
- NAMS Nasdaq
- GOF Nasdaq
- Market Cap
- NAMS 2.2B
- GOF 2.4B
- IPO Year
- NAMS N/A
- GOF N/A
- Fundamental
- Price
- NAMS $18.11
- GOF $14.71
- Analyst Decision
- NAMS Strong Buy
- GOF
- Analyst Count
- NAMS 6
- GOF 0
- Target Price
- NAMS $42.83
- GOF N/A
- AVG Volume (30 Days)
- NAMS 694.5K
- GOF 789.2K
- Earning Date
- NAMS 05-08-2025
- GOF 01-01-0001
- Dividend Yield
- NAMS N/A
- GOF 15.42%
- EPS Growth
- NAMS N/A
- GOF N/A
- EPS
- NAMS N/A
- GOF N/A
- Revenue
- NAMS $47,140,000.00
- GOF N/A
- Revenue This Year
- NAMS N/A
- GOF N/A
- Revenue Next Year
- NAMS N/A
- GOF N/A
- P/E Ratio
- NAMS N/A
- GOF N/A
- Revenue Growth
- NAMS 586.97
- GOF N/A
- 52 Week Low
- NAMS $14.06
- GOF $10.96
- 52 Week High
- NAMS $27.29
- GOF $16.76
- Technical
- Relative Strength Index (RSI)
- NAMS 47.80
- GOF 53.94
- Support Level
- NAMS $16.79
- GOF $14.29
- Resistance Level
- NAMS $19.58
- GOF $14.89
- Average True Range (ATR)
- NAMS 0.94
- GOF 0.15
- MACD
- NAMS -0.12
- GOF 0.02
- Stochastic Oscillator
- NAMS 47.07
- GOF 70.00
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.